Cardinal Health (CAH) Stock Overview
Operates as a healthcare services and products company in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 4/6 |
CAH Community Fair Values
Create NarrativeSee what 69 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cardinal Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$199.23 |
| 52 Week High | US$233.60 |
| 52 Week Low | US$137.75 |
| Beta | 0.54 |
| 1 Month Change | -5.66% |
| 3 Month Change | -10.56% |
| 1 Year Change | 29.95% |
| 3 Year Change | 134.50% |
| 5 Year Change | 255.26% |
| Change since IPO | 14,921.70% |
Recent News & Updates
Narrative Update • May 11
CAH: Theranostics Capacity Expansion Will Support Future Upside Despite Mixed Street Revisions
Analysts have reduced the Cardinal Health fair value estimate by $3.00 to $245.27, reflecting updated assumptions for growth, margins, discount rate, and a higher future P/E that align with the recent mix of lowered and raised Street price targets. Analyst Commentary Recent Street research on Cardinal Health reflects a mix of optimism and caution, with several firms adjusting price targets and at least one new bullish initiation.Analysis Article • May 07
Cardinal Health's (NYSE:CAH) Solid Earnings Have Been Accounted For Conservatively
Cardinal Health, Inc.'s ( NYSE:CAH ) recent earnings report didn't offer any surprises, with the shares unchanged over...Recent updates
Narrative Update • May 11
CAH: Theranostics Capacity Expansion Will Support Future Upside Despite Mixed Street Revisions
Analysts have reduced the Cardinal Health fair value estimate by $3.00 to $245.27, reflecting updated assumptions for growth, margins, discount rate, and a higher future P/E that align with the recent mix of lowered and raised Street price targets. Analyst Commentary Recent Street research on Cardinal Health reflects a mix of optimism and caution, with several firms adjusting price targets and at least one new bullish initiation.Analysis Article • May 07
Cardinal Health's (NYSE:CAH) Solid Earnings Have Been Accounted For Conservatively
Cardinal Health, Inc.'s ( NYSE:CAH ) recent earnings report didn't offer any surprises, with the shares unchanged over...Narrative Update • Apr 23
CAH: Specialty Expansion And Theranostics Capacity Will Support Future Upside
Analysts have made a slight trim to the Cardinal Health analyst price target, nudging it down by about $1 to reflect updated fair value and P/E assumptions, while still pointing to strength across the business and guidance that they view as reasonable. Analyst Commentary Recent Street research on Cardinal Health shows a cluster of price target changes, with several upward revisions and one material trim, as analysts update assumptions around fair value and P/E while reacting to the company’s guidance and underlying business trends.Narrative Update • Apr 08
CAH: Specialty Expansion And Distribution Onboarding Will Support Future Upside
Analysts have nudged their consolidated price targets for Cardinal Health, including moves such as Evercore ISI's $20 trim along with multiple recent increases from firms like Barclays, Wells Fargo, Morgan Stanley, Baird, Mizuho, TD Cowen, BofA, Leerink and Citi, as they point to broad strength across the business and updated models after guidance changes. Analyst Commentary Recent research updates around Cardinal Health cluster around a broadly constructive tone, with most firms adjusting their models after the latest guidance changes and commentary on business trends.Narrative Update • Mar 24
CAH: Specialty Expansion And Core Resiliency Will Support Future Upside
Analysts have inched their blended price target for Cardinal Health higher by about $0.33 to $249.60, citing updated models that reflect consistent strength across the business and a series of recent target raises from major firms. Analyst Commentary Recent research updates cluster around higher price targets and refreshed models, with most commentary pointing to consistent execution and a more confident view on Cardinal Health's core franchises and newer specialty efforts.Narrative Update • Mar 10
CAH: Specialty Expansion And Core Resiliency Will Drive Future Upside Potential
Our analyst price target for Cardinal Health has nudged up by about $1 to $249.27, reflecting broadly higher Street targets in the mid $240s to high $250s as analysts factor in strength across the business, repeated guidance raises and growing confidence in the specialty and distribution franchises. Analyst Commentary Street research has been broadly constructive on Cardinal Health, with a series of target moves and rating changes clustered over recent months.Narrative Update • Feb 24
CAH: Specialty Expansion And Core Resiliency Will Guide Balanced Future Risk Reward
Our updated fair value estimate for Cardinal Health has moved to $248.80, up from $243.07. This reflects analysts' higher price targets tied to stronger guidance, resilient core distribution, and growing specialty assets.Narrative Update • Feb 09
CAH: Specialty Expansion And Core Resiliency Will Shape Future Risk Reward
Analysts have nudged their price expectations for Cardinal Health higher, with our fair value estimate moving about $13 higher to roughly $243 per share. This change reflects updated guidance, ongoing strength in the core distribution business, and continued build out of specialty assets, along with a modestly lower future P/E assumption and a slightly higher profitability outlook.Seeking Alpha • Feb 07
Cardinal Health Q2 2026 Review: An Epitome Of Resilience And Earnings Power (Upgrade)
Summary Cardinal Health is upgraded to a buy after Q2 2026 delivered robust revenue, margin expansion, and raised full-year guidance. Q2 revenue grew 19% YoY to $65.6B, with non-GAAP EPS up 36% and broad-based segment strength, especially in pharmaceuticals. Management executed $750M in share repurchases YTD, underscoring commitment to capital return and reducing outstanding shares by 2.5%. Valuation rerating is underway as CAH’s growth momentum accelerates, though reimbursement pressure from US healthcare reforms remains a key risk. Read the full article on Seeking AlphaNarrative Update • Jan 26
CAH: Specialty Expansion And Core Distribution Trends Will Shape Future Risk Reward
Analysts have nudged their price expectations for Cardinal Health higher, with the fair value estimate moving about $8 to $230.27 as they factor in updated guidance, resilient core distribution trends, and a slightly higher future P/E assumption supported by a series of recent price target increases across the Street. Analyst Commentary Recent Street research paints a generally constructive picture around Cardinal Health, with several firms lifting price targets and, in one case, upgrading the rating.Narrative Update • Jan 11
CAH: Specialty Expansion And Policy Shifts Will Shape Future Risk Reward Balance
Analysts have nudged their price targets on Cardinal Health higher, reflected in our fair value estimate moving from $216.60 to $222.20. They highlight strong core Pharma execution, improving margins, and growing confidence in the specialty build out and Solaris driven earnings outlook.Narrative Update • Dec 27
CAH: Future EPS Momentum And Policy Shifts Will Define Risk Reward Balance
Analysts have nudged their average price targets for Cardinal Health higher into the low $210s, citing stronger than expected EPS momentum, sustained core Pharma outperformance, and incremental upside from the Solaris acquisition and broader industry demand. Analyst Commentary Recent Street research has tilted decisively positive on Cardinal Health, with multiple firms lifting price targets into the $210 to $220 range as they recalibrate earnings and valuation assumptions following stronger than expected results and the Solaris acquisition.Narrative Update • Dec 13
CAH: Future EPS Momentum And Policy Risks Will Shape Medium-Term Outlook
Analysts have nudged their blended price target on Cardinal Health slightly higher, with fair value rising about $2 to roughly $217, citing stronger than expected EPS momentum, resilient core Pharma performance, and increased confidence in the company achieving its 12% to 14% long term EPS growth algorithm. Analyst Commentary Street commentary on Cardinal Health remains broadly constructive, with several bullish analysts lifting price targets into the low $200s and emphasizing both near term earnings momentum and the durability of the company growth algorithm.Narrative Update • Nov 29
CAH: Earnings Momentum and Industry Uncertainty Will Shape Outlook This Year
Cardinal Health's analyst price target has increased modestly from $212.43 to $214.71. Analysts cite stronger-than-expected quarterly results and raised guidance, driven by continued execution across core segments and strategic acquisitions.Narrative Update • Nov 14
CAH: Guidance Will Remain Under Scrutiny Amid Industry and Regulatory Pressures
Cardinal Health's analyst price target has been raised from approximately $189 to over $212 per share. Analysts cite strong recent earnings, raised guidance, and continued execution on strategic priorities as key drivers of the upward revision.Analysis Article • Nov 08
Cardinal Health's (NYSE:CAH) Dividend Will Be $0.5107
Cardinal Health, Inc. ( NYSE:CAH ) has announced that it will pay a dividend of $0.5107 per share on the 15th of...Analysis Article • Nov 05
Why Investors Shouldn't Be Surprised By Cardinal Health, Inc.'s (NYSE:CAH) 26% Share Price Surge
Cardinal Health, Inc. ( NYSE:CAH ) shareholders have had their patience rewarded with a 26% share price jump in the...Narrative Update • Oct 30
CAH: Core Pharmaceutical Trends And Automation Will Shape Upcoming Earnings Performance
Cardinal Health's analyst price target has increased from $180 to $216 per share. This reflects stronger confidence in the company's core pharmaceutical business and its ability to deliver on long-term earnings targets, according to recent analyst commentary following robust quarterly results.Analysis Article • Sep 23
Cardinal Health (NYSE:CAH) Has Affirmed Its Dividend Of $0.5107
The board of Cardinal Health, Inc. ( NYSE:CAH ) has announced that it will pay a dividend of $0.5107 per share on the...Analysis Article • Jul 28
Here's Why We Think Cardinal Health (NYSE:CAH) Might Deserve Your Attention Today
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analysis Article • Jun 20
Investors Still Waiting For A Pull Back In Cardinal Health, Inc. (NYSE:CAH)
With a price-to-earnings (or "P/E") ratio of 25.4x Cardinal Health, Inc. ( NYSE:CAH ) may be sending bearish signals at...Seeking Alpha • Jan 09
Cardinal Health: Demand For Medical Supplies To Grow, But Negative Equity Persists
Summary Cardinal Health gets downgraded to a hold, from my buy rating last February, agreeing with the Seeking Alpha quant system rating. While macro-level demand for medical supplies is expected to keep growing, CAH is plagued by negative equity. Although the firm has a positive earnings outlook for FY25, its profit margin lags behind similar peers and could use improvement. Dividend growth has not been anything steady in the last decade. A key risk in this segment is that of regulatory and legal costs involving medical products and drugs. Read the full article on Seeking AlphaSeeking Alpha • Nov 04
Cardinal Health Q1 Earnings: Margins Signal More Upside
Summary Cardinal Health's Q1 2025 earnings reaffirm my buy rating due to a strengthening pharmacy business and industry tailwinds. Despite initial market overreaction to 2025 guidance, Cardinal Health's management is transparently mitigating risks. A DCF analysis suggests a price target of $128 for CAH stock, offering a 17% upside. Read the full article on Seeking Alpha
New Narrative • Aug 19
Expanding Oncology And Specialty Solutions To Drive Revenue And Profitability Amidst Evolving Challenges
Cardinal Health's emphasis on enhancing its Specialty Solutions in oncology and strategic partnerships aims to boost revenue growth.Seeking Alpha • Aug 01
Cardinal Health: Growth Headwinds Ahead
Summary Cardinal Health's recent dividend raise (about 1%) reflects growth pressure ahead. With a ~13x P/E, valuation seems reasonable on the surface. However, when adjusted for growth, the current valuation points to an unfavorable return profile. I see large odds for growth headwinds to persist due to cost pressure and competition from online pharmacies and direct distributors. Read the full article on Seeking AlphaShareholder Returns
| CAH | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 6.9% | -0.9% | -1.0% |
| 1Y | 30.0% | 9.5% | 23.3% |
Return vs Industry: CAH exceeded the US Healthcare industry which returned 9.5% over the past year.
Return vs Market: CAH exceeded the US Market which returned 23.3% over the past year.
Price Volatility
| CAH volatility | |
|---|---|
| CAH Average Weekly Movement | 3.7% |
| Healthcare Industry Average Movement | 7.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CAH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CAH's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 55,392 | Jason Hollar | www.cardinalhealth.com |
Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home.
Cardinal Health, Inc. Fundamentals Summary
| CAH fundamental statistics | |
|---|---|
| Market cap | US$46.93b |
| Earnings (TTM) | US$1.56b |
| Revenue (TTM) | US$250.74b |
30.0x
P/E Ratio0.2x
P/S RatioIs CAH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CAH income statement (TTM) | |
|---|---|
| Revenue | US$250.74b |
| Cost of Revenue | US$241.32b |
| Gross Profit | US$9.42b |
| Other Expenses | US$7.86b |
| Earnings | US$1.56b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.64 |
| Gross Margin | 3.76% |
| Net Profit Margin | 0.62% |
| Debt/Equity Ratio | -333.7% |
How did CAH perform over the long term?
See historical performance and comparisonDividends
1.0%
Current Dividend Yield31%
Payout RatioDoes CAH pay a reliable dividends?
See CAH dividend history and benchmarks| Cardinal Health dividend dates | |
|---|---|
| Ex Dividend Date | Jul 01 2026 |
| Dividend Pay Date | Jul 15 2026 |
| Days until Ex dividend | 41 days |
| Days until Dividend pay date | 55 days |
Does CAH pay a reliable dividends?
See CAH dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/20 21:49 |
| End of Day Share Price | 2026/05/20 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cardinal Health, Inc. is covered by 32 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Eric Coldwell | Baird |
| Lawrence Marsh | Barclays |